Dare Bioscience, Inc. (NASDAQ:DARE) has scheduled a conference call for 12th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.darebioscience.com
To participate on the live call, please dial (844) 831-3031 U.S. or (443) 637-1284 Outside U.S., and the passcode is 6519434
Earnings Expectation
Dare Bioscience, Inc. a clinical-stage, women biopharmaceutical company, is expected to report third quarter earnings results, before market open, on Thursday 12th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.17 per share from revenue of $ 0.18 million. Looking ahead, the full year loss are expected at $ 0.71 per share on the revenues of $ 0.53 million.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing womens reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy.
